Navigation Links
Repligen to Present at the Rodman & Renshaw 11th Annual Healthcare Conference Wednesday, September 9th, 2:25 p.m. EDT
Date:9/2/2009

gement's strategy, plans and objectives for future operations, plans and objectives for product development, plans and objectives for present and future clinical trials and results of such trials, plans and objectives for regulatory approval, litigation, intellectual property, product development, manufacturing plans and performance such as the anticipated growth in the monoclonal antibody market and our other target markets and projected growth in product sales, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the success of current and future collaborative relationships, the market acceptance of our products, our ability to compete with larger, better financed pharmaceutical and biotechnology companies, new approaches to the treatment of our targeted diseases, our expectation of incurring continued losses, our uncertainty of product revenues and profits, our ability to generate future revenues, our ability to raise additional capital to continue our drug development programs, the success of our clinical trials, our ability to develop and commercialize products, our ability to obtain required regulatory approvals, our compliance with all Food and Drug Administration regulations, our ability to obtain, maintain and protect intellectual property rights for our products, the risk of litigation regarding our intellectual property rights, our limited sales and manufacturing capabilities, our dependence on third-party manufacturers and value added resellers, our ability to hire and retain skilled personnel, our volatile stock price, and other risks detailed in Repligen's filings with the Securities and Exchange Commission. Repligen assumes no obligation to update any forward-looking information contained in this press release or with respect to the announcements describe
'/>"/>
SOURCE Repligen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Repligen Elects Glenn L. Cooper, M.D. to the Board of Directors
2. Repligen Reports First Quarter Fiscal Year 2010 Financial Results
3. Repligen Announces Conference Call of First Quarter Fiscal Year 2010 Results
4. Repligen Reports Fourth Quarter and Fiscal Year 2009 Financial Results
5. Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2009 Results
6. Repligen to Present at the Cowen and Company 29th Annual Healthcare Conference Monday, March 16th, 2:25 p.m. EDT
7. Repligen Reports Third Quarter Fiscal Year 2009 Financial Results
8. Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST
9. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
10. Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
11. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... Oct. 1, 2014 Pfanstiehl has announced ... EP), manufactured in the USA ... long been recognized for playing a key role ... body of evidence that media supplementation with mannose ... protein glycosylation," according to Dr. Christopher Wilcox ...
(Date:10/1/2014)... In response to its clients’ ... sales, training and consumer engagement challenges, digital ... applications to turn their clients’ visions into reality. ... mobile app creations, are now featured on its ... with Toyota, StudioPMG created a robust cross-platform mobile ...
(Date:10/1/2014)... San Francisco, California (PRWEB) October 01, 2014 ... grant from the National Science Foundation to expand their ... approaches to build and modify DNA. The Small Business ... help commercialize the “j5” technology under exclusive license from ... the Joint BioEnergy Institute , an LBNL laboratory ...
(Date:9/30/2014)... German . , ... in a semiconductor layer. Quantum dots are small structures that ... a short laser pulse is fired at the photonic crystal, ... a change in the electromagnetic field around it. This change ... by the dot. As soon as the refractive index recovers ...
Breaking Biology Technology:Pfanstiehl Launches cGMP-produced Mannose for Cell Culture Media Optimization & Glycoprotein Biosynthesis 2Digital Agency Studio PMG Launches New Case Studies on Website 2TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3Ultrafast remote switching of light emission 2
(Date:9/30/2014)... your doctor to know what goes wrong with your muscles ... to know what "normal" actually is. That,s where a new ... FASEB Journal comes in. In the ... set of molecules that can help scientists "see" which genes ... more, they found never-before-detected gene activity and that men have ...
(Date:9/30/2014)... 30, 2014  Spectra Automation, a trusted ... biotech and power generation industries, announced today ... Manager, an easy-to-use and cost-effective data collection, ... development laboratories. Most upstream ... analyzer systems. Accessing and consolidating data from ...
(Date:9/30/2014)... of The Economist,s prestigious Innovation awards 2014 will speak ... the JW Marriott Hong Kong on Friday, October 10 th ... and the lessons those hold for others. The awards, which recognises ... decade, will be presented at a ceremony in Hong ... the first time the ceremony has come to Asia ...
Breaking Biology News(10 mins):Scientists identify which genes are active in muscles of men and women 2Spectra Automation Introduces RECONN Bioprocess Manager 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 3Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 4Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 5Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 6Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 7
... restored significant bladder function through nerve regeneration in rats with ... a traditional nerve bridge graft with a novel combination of ... cells from the thoracic level to the lower spinal cord ... issue of the Journal of Neuroscience . Neuroscientists ...
... been no research dedicated to the importance of Vitamin ... However, over the past few years, researchers at the ... Cardiovascular Surgery Program teamed with the Canadian Critical Care ... on the Vitamin D status of infants and children, ...
... UT Arlington water resources engineer is developing a first-of-its-kind ... to more effectively dispatch emergency personnel to save lives ... associate professor in the Department of Civil Engineering, has ... Worth, the National Science Foundation and the National Weather ...
Cached Biology News:Bladder function restored in animals with severe spinal cord injury 2Bladder function restored in animals with severe spinal cord injury 3Research shows Vitamin D levels drop after pediatric heart surgery, increasing sickness 2UT Arlington engineer to design prototype that predicts flash flooding 2
4-Hydroxy-3-nitrophenylacetyl hapten is conjugated to KLH (Keyhole Limpet Hemocyanin) lysine through amide bonds....
Estrogen Receptor (ER) Competitor Assay Kits Green for Estrogen Receptors-alpha and -beta (ER-Alpha and ER-Beta) are ideal for screening novel estrogen receptor binding compounds and endocrine disrup...
Human Aminopeptidase P2/XPNPEP2 Affinity Purified PAb ENTREZ GeneID: 7512...
in vitro Translation, Accessory Products...
Biology Products: